＜ 循環器疫学研究のあゆみ ＞
| 背景，治療法，診断法など | 主要ガイドライン・臨床試験 （  日本， 臨床試験） |
年代 | おもな疫学研究 （ 日本人を対象とした／日本人を含む研究， メタ解析， 登録研究， 派生研究） |
おもなリスク評価ツール （  : 冠動脈疾患， : 脳卒中，日本） |
|---|---|---|---|---|
|
1930 | |||
|
1940 |
|
||
|
1950 |
|
||
|
|
1960 |
|
|
|
|
1970 |
|
|
|
|
1980 |
|
|
|
|
1990 |
|
|
|
|
2000 |
|
|
|
|
2010 |
|
|
|
2020 | |||
| 4S: Scandinavian Simvastatin Survival Study, ABPM: 自由行動下血圧測定, ACC: American College of Cardiology, ACCORD-BP: Action to Control Cardiovascular Risk in Diabetes Blood Pressure, ACE: アンジオテンシン変換酵素, ADVANCE-BP: Action in Diabetes and Vascular Disease-Preterax and Diamicron MR Controlled Evaluation, AED: 自動体外式除細動器, AF: 心房細動, AHA: 米国心臓協会, ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, AMI: 急性心筋梗塞, APCSC: Asia Pacific Cohort Studies Collaboration, ARB: アンジオテンシンII受容体遮断薬, ARIC: Atherosclerosis Risk in Communities Study, ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm, ASCOT-LLA: Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm, ASCVD: atherosclerotic cardiovascular disease, CARDIA: Coronary Artery Disease Risk Development in Young Adult, CHARM: Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity, CHS: Cardiovascular Health Study, CIBIS II: Cardiac Insufficiency Bisoprolol Study II, CIRCS: Circulatory Risk in Communities Study, CKD: 慢性腎臓病, CKD-JAC: 日本CKDコホート研究, CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study, COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival, DIG: Digitalis Investigation Group, DOAC: 直接作用型経口抗凝固薬, DPP-4: ジペプチジルペプチダーゼ-4, ELITE II: Evaluation of Losartan in the Elderly Study II, EPOCH-JAPAN: Evidence for Cardiovascular Prevention From Observational Cohorts in Japan, ERA JUMP: Electron-Beam Tomography and Risk Assessment among Japanese and US Men in the Post World War II Birth Cohort, ERFC: Emerging Risk Factors Collaboration, ESC: 欧州心臓病学会, ESH: 欧州高血圧学会, FDA: 米国食品医薬品局, FRS: フラミンガムリスクスコア, GL: ガイドライン, GLP-1: グルカゴン様ペプチド-1, HOPE: Heart Outcomes Prevention Evaluation, HOT: Hypertension Optimal Treatment, HPFS: Health Professionals Follow-up Study, hsCRP: 高感度CRP, HYVET: Hypertension in the Very Elderly Trial, ICD: 植え込み型除細動器, IDACO: The International Database of Ambulatory Blood Pressure in relation to Cardiovascular Outcome, IDHOCO: The International Database of Home blood pressure in relation to Cardiovascular Outcome, IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trial, INTERMAP: International study of macro- and micronutrients and blood pressure, INTERSALT: International study of salt and blood pressure, iPS: 人工多能性幹細胞, ISH: 国際高血圧学会, IVUS: 血管内超音波, JACC: Japan Collaborative Cohort Study, JALS: Japan Arteriosclerosis Longitudinal Study, JAS: 日本動脈硬化学会, JELIS: Japan EPA Lipid Intervention Study, JMS: 自治医科大学, JNC: 米国合同委員会, JPHC: Japan Public Health Center-based prospective Study, JSH: 日本高血圧学会, JUPITER: Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin, LIPID: Long-Term Intervention with Pravastatin in Ischaemic Disease, LRC-CPPT: Lipid Research Clinics Coronary Primary Prevention Trial, MEGA: Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese, MESA: Multi-Ethnic Study of Atherosclerosis, MetS: メタボリックシンドローム, MRFIT: Multiple Risk Factor Intervention Trial, MRI: 核磁気共鳴イメージング, NCEP-ATP: 米国コレステロール教育プログラム成人治療委員会, NHANES: National Health and Nutrition Examination Survey, NHS: Nurses' Health Study, NICS-EH: National Intervention Cooperative Study in Elderly Hypertensives, NI-HON-SAN: Nippon-Honolulu-San Francisco, OACIS: Osaka Acute Coronary Insufficiency Study, PCSK9: 前駆蛋白転換酵素サブチリシン/ケキシン9型, PHS: Physicians' Health Study, PROGRESS: Perindopril Protection against Recurrent Stroke Study, PSC: Prospective Cohort Studies Collaboration, RALES: Randomized Aldactone Evaluation Study, REACH Registry: Reduction of Atherothrombosis for Continued Health Registry, SCORE: Systematic Coronary Risk Estimation, SESSA: 滋賀動脈硬化疫学研究, SHEP: Systolic Hypertension in the Elderly Program, SHIFT: Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial, SPRINT: Systolic Blood Pressure Intervention Trial, Syst-Eur: Systolic Hypertension in Europe, TC: 総コレステロール, TG: トリグリセライド, tPA: 組織型プラスミノゲン活性化因子, UKPDS: UK Prospective Diabetes Study, VA: Veterans Affairs, VALUE: Valsartan Antihypertensive Long-term Use Evaluation, WHI: Women's Health Initiative, WHO: 世界保健機関, WHS: Women's Health Study, WOSCOPS: West of Scotland Coronary Prevention Study | ||||